Genetic Ablation and Multi‐Omics Profiling Reveal CEP55 as a Key Driver of Tumorigenesis in Diverse Cancer Models
Advanced Science · 2026
DOI: 10.1002/advs.76782 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Behnam Rashidieh und 22 weiteren Autor:innen. Beteiligte Einrichtung: Mater Research Institute, The University of Queensland, Translational Research Institute, Brisbane, QLD, Australia. Hauptthemen laut MEDLINE: Carcinogenesis, Centrosomal Associated Proteins, Cell Cycle Proteins, Neoplasms. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health & Medical Research Council (NH&MRC) Program, National Breast Cancer Foundation (NBCF) Investigator Initiated Research Scheme, Victorian Cancer Agency Mid-Career Research Fellowships.
Abstract (Originalsprache)
CEP55, a centrosomal protein frequently overexpressed in multiple cancers, is implicated in regulation of genomic instability and PI3K/AKT pathway activation, yet its role in tumor progression and the tumor microenvironment remains incompletely defined. Here, we developed an inducible Cep55 knockout (KO) mouse model and complementary primary, immortalized, and transformed mouse embryonic fibroblast (MEF) systems and employ integrative multi‐omics analyses to define CEP55‐driven mechanisms and validated findings in human cancer datasets. Cep55 deletion is well tolerated in adult tissues but significantly delays tumor onset and progression in E1A/Ras‐driven models and prolongs survival in PTEN‐deficient cancer models. Mechanistically, spatial transcriptomic and proteomic analyses revealed that CEP55 regulates extracellular matrix (ECM) remodeling, integrin signaling, and cell adhesion pathways, AKT/ERK signaling and cellular stress responses. Importantly, loss of Cep55 also reprograms the tumor immune microenvironment, reducing tumor‐supportive macrophage polarization and enhancing antigen‐specific CD8 + T‐cell responses in vitro. Collectively, these findings demonstrate that CEP55 is dispensable for adult tissue homeostasis but plays a critical role in tumor progression by coordinating oncogenic signaling, extracellular matrix dynamics, and tumor–immune interactions and highlight it as a potential therapeutic target in aggressive and immune‐resistant cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mater Research Institute, The University of Queensland, Translational Research Institute, Brisbane, QLD, Australia.
- Cancer Research Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
- Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Queensland, Australia.
- School of Environment and Science, Griffith University, Brisbane, QLD, Australia.
- Department of Molecular & Cellular Biology, University of Adelaide, School of Biological Sciences, Adelaide, SA, Australia.
- South Australian Health and Medical Research Institute, Adelaide, SA, Australia.
ORCID-Profile: Behnam Rashidieh, Yuanhao Yang, Phillip Theron, Parinaz Ahangar, Nicholas J Westra van Holthe, J Alejandro Lopez, John Finnie, Antonella Papa, Quan Nguyen, Pirjo M Apaja
Förderung
- National Health & Medical Research Council (NH&MRC) Program
- National Breast Cancer Foundation (NBCF) Investigator Initiated Research Scheme
- Victorian Cancer Agency Mid-Career Research Fellowships
Zitieren
APA
Rashidieh, B., Yang, Y., Bain, A. L., Theron, P., Vosloo, C., Keshvari, S., Ahangar, P., Bowden, B., Tria, S. M., Wang, B. B., Isenmann, S., van Holthe, N. J. W., Xiong, Z., Vu, H., Sharma, S., Sengal, A., Lopez, J. A., Finnie, J., Papa, A., …, & Khanna, K. K. (2026). Genetic Ablation and Multi‐Omics Profiling Reveal CEP55 as a Key Driver of Tumorigenesis in Diverse Cancer Models. Advanced Science. https://doi.org/10.1002/advs.76782
Vancouver
Rashidieh B, Yang Y, Bain AL, Theron P, Vosloo C, Keshvari S, et al. Genetic Ablation and Multi‐Omics Profiling Reveal CEP55 as a Key Driver of Tumorigenesis in Diverse Cancer Models. Advanced Science. 2026. doi:10.1002/advs.76782
BibTeX
@article{Rashidieh2026,
author = {Rashidieh, Behnam and Yang, Yuanhao and Bain, Amanda Louise and Theron, Phillip and Vosloo, Catharina and Keshvari, Sahar and Ahangar, Parinaz and Bowden, Brydie and Tria, Simon M and Wang, Ben B and Isenmann, Sandra and van Holthe, Nicholas J Westra and Xiong, Zherui and Vu, Hani and Sharma, Sowmya and Sengal, Asmerom and Lopez, J Alejandro and Finnie, John and Papa, Antonella and Duijf, Pascal H G and Nguyen, Quan and Apaja, Pirjo M and Khanna, Kum Kum},
title = {Genetic Ablation and Multi‐Omics Profiling Reveal CEP55 as a Key Driver of Tumorigenesis in Diverse Cancer Models},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.76782}
}
EUVIMED